Retrospective analysis of the preparation and application of immunotherapy in cancer treatment (Review)
Cosentyx (Secukinumab Injection): Uses, Dosage, Side Effects, Interactions, Warning
Effect of IL-17A blockade with secukinumab in autoimmune diseases | Annals of the Rheumatic Diseases
-01fd-01.png "Secukinumab")
Secukinumab
Cosentyx (secukinumab) for Treatment of Plaque Psoriasis - Clinical Trials Arena
Ankylosing Spondylitis Treatment | COSENTYX® (secukinumab)
Secukinumab: Uses, Interactions, Mechanism of Action | DrugBank Online
Secukinumab Overview - Creative Biolabs
The interleukin-17 (IL-17) pathway in the pathogenesis of psoriatic... | Download Scientific Diagram
CIMB | Free Full-Text | The Treatment with Interleukin 17 Inhibitors and Immune-Mediated Inflammatory Diseases | HTML
Interleukin-17 and Interleukin-23: A Narrative Review of Mechanisms of Action in Psoriasis and Associated Comorbidities | SpringerLink
Ankylosing Spondylitis Treatment | COSENTYX® (secukinumab)
Spotlight on brodalumab in the treatment of moderate-to-severe plaque | DDDT
Frontiers | Combining Understanding of Immunological Mechanisms and Genetic Variants Toward Development of Personalized Medicine for Psoriasis Patients | Genetics
The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses: Trends in Immunology
Effect of IL-17A blockade with secukinumab in autoimmune diseases | Annals of the Rheumatic Diseases
Frontiers | Mini Review: New Treatments in Psoriatic Arthritis. Focus on the IL-23/17 Axis | Pharmacology
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial - ScienceDirect
Profile of secukinumab in the treatment of psoriasis: current perspect | TCRM
Rheumatology Indications | COSENTYX® (secukinumab)
Frontiers | A Review of the Efficacy and Safety for Biologic Agents Targeting IL-23 in Treating Psoriasis With the Focus on Tildrakizumab | Medicine
SILIQ (brodalumab) | How SILIQ is an Innovative Psoriasis Treatment
Secukinumab treatment in new‐onset psoriasis: aiming to understand the potential for disease modification – rationale and design of the randomized, multicenter STEPIn study - Iversen - 2018 - Journal of the European
Interleukin 17, inflammation, and cardiovascular risk in patients with psoriasis - Journal of the American Academy of Dermatology
Paradoxical gastrointestinal effects of interleukin-17 blockers | Annals of the Rheumatic Diseases
Treat Psoriasis: A New Era is Coming - European Medical Journal
How COSENTYX® Works to Treat Ankylosing Spondylitis | COSENTYX (secukinumab)
